Compare TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $213.81 (market cap $39.15B), while Vertex Pharmaceuticals Incorporated trades at $509.5 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.3× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock for 111 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| TTWO | VRTX | |
|---|---|---|
Market Cap | $39.15B | $127.55B |
Volume | 2,708,429 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $262.29 | $557.96 |
52-Week Low | $189.69 | $407.37 |
Typical Hold Time | 111 Days | 120 Days |
Enterprise Value | $40.27B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Take-Two Interactive (TTWO) trades at $213.88, up 4.84% with bullish technical signals and strong analyst support. The company shows mixed fundamentals with revenue growth to $5.63B but negative net income of -$4.48B, though recent earnings beats and the upcoming GTA VI launch provide optimism. Technical indicators show the stock trading near resistance at $215 with RSI suggesting potential overbought conditions.
The outlook remains positive driven by GTA VI's November launch, with analysts projecting 37% upside to $292.30 consensus target. Key risks include persistent profitability challenges, high debt levels, and execution pressure on major game releases. Institutional ownership trends show continued confidence despite recent financial headwinds.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
